Profile: Sanofi SA (SNY.N)
7 Dec 2016
Sanofi, formerly Sanofi-Aventis, incorporated on May 11, 1994, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company has three operating segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from its subsidiary, Genzyme Corporation. Its pharmaceuticals portfolio consists of products and a range of prescription medicines, generic medicines and consumer health products. The Pharmaceuticals segment also includes associates with activities related to pharmaceuticals. The Vaccines segment is dedicated to vaccines, including research, development, production and marketing. The Vaccines segment includes the Sanofi Pasteur MSD joint venture. The Animal Health segment includes the research, development, production and marketing activities of Merial, which offers a range of medicines and vaccines for a range of animal species. The Company's Animal Health segment includes its subsidiaries, Merial, Inc. and Merial S.A.S. It also operates in the Other segment, which includes the effects of retained commitments in respect of divested activities.
The Company's Pharmaceuticals segment includes marketed products grouped into the fields of diabetes, cardiovascular disease, rare diseases, multiple sclerosis (MS) and oncology. It also has a presence in consumer healthcare and generics. Its principal diabetes products are Lantus and Toujeo, which are long acting analogs of human insulin; Amaryl, which is a sulfonylurea; Apidra, which is a rapid acting analog of human insulin; Insuman, which is a human insulin, and Lyxumia (lixisenatide), which is a once-daily prandial glucagon-like peptide (GLP)-1 receptor agonist. Its cardiovascular products include Praluent, which is a human monoclonal antibody (mAb) that blocks the interaction of proprotein convertase subtilisin kexin type 9 (PSCK9) with low-density lipoprotein (LDL) receptors, and Multaq (dronedarone), which is an anti-arrhythmic drug.
The Company's rare diseases business is focused on products for the treatment of rare genetic diseases and other chronic debilitating diseases, including lysosomal storage disorders, and offers products, such as Cerezyme, Cerdelga and Fabrazyme. Its MS franchise consists of Aubagio (teriflunomide), a once-daily oral immunomodulator, and Lemtrada (alemtuzumab), a monoclonal antibody. It has a portfolio of approximately 10 marketed products in oncology, including Jevtana, Eloxatin, Taxotere, Thymoglobulin and Zaltrap. Its prescription products and other products include Plavix/Iscover, Aprovel/ Avapro/Karvea and Renagel.
Human Vaccines (Vaccines)
The Company's Vaccines segment offers a range of vaccines. The Company's vaccine products consists of pediatric, combination and poliomyelitis (polio) vaccines, including Pentaxim and Hexaxim; influenza vaccines, including Fluzone and Intradermal (ID) trivalent influenza vaccines; adult and adolescent boosters, including Adacel and Repevax; meningitis and pneumonia vaccines, and travel and endemic vaccines, including IMOJEV.
The Company's Animal Health segment includes Merial's products. The Company offers a range of products for animals (both livestock and pets). These products include Frontline, which is a topical flea and tick anti-parasitic intended for dogs and cats; Heartgard, which is a parasiticide for control of heartworm in pets; Nexgard, which is an oral anti-parasitic for the treatment and prevention of fleas and ticks in dogs, and Vaxxitek, which is vector vaccine for protecting chickens against infectious bursal disease (IBD) and Marek's disease.
The Company competes with Novo Nordisk, Boehringer Ingelheim, Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb, Novartis, Shire, Pfizer, Biogen Idec Inc., Teva Pharmaceuticals Industries, Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Amgen, GlaxoSmithKline, Mylan, Actavis, Zoetis, Elanco, Virbac, Ceva and Vetoquinol.
54 rue la Boetie, Paris 8
Company Web Links
- Sanofi exploring bid for Actelion amid J&J talks: Bloomberg
- Novo, Sanofi go head to head as FDA clears new diabetes drugs
- UPDATE 2-Novo, Sanofi go head to head as FDA clears new diabetes drugs
- BRIEF-Sanofi sees Soliqua costing about same as a GLP-1 drug in U.S.
- BRIEF-Zealand Pharma: US FDA approves Soliqua 100/33 for treatment of adults with type 2 diabetes